MedTrace Logo

Straberi Epistamp Needling Treatment For Skin Rejuvenation

NCT04742803 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-12-06

No results posted yet for this study

Summary

This pilot study will expand knowledge and application needling using the Epistamp device for the improvement of a new vitalized epidermal layer with new vibrant active cells, supported by more robust collagen and elastin fine lines, deep wrinkles, and collagen production.

Conditions

  • Wrinkle
  • Elastic Skin
  • Collagen Degeneration

Interventions

DEVICE

Straberi Epistamp Microneedling Treatment

The patient's entire face will be treated with the Straberi Epistamp needling device. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm

Sponsors & Collaborators

  • Lavish Beauty

    collaborator UNKNOWN

  • Universal Skincare Institute

    lead OTHER

Principal Investigators

  • Maurice Wright, MD · Columbia University/ Harlem Hospital

  • Leslie L Nesbitt · Universal Skincare

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-23
Primary Completion
2023-06-30
Completion
2023-10-12
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04742803 on ClinicalTrials.gov